ESMO 2017: CHECKMATE 067 update

Last weekend, we also got the 3 year- update on CHECKMATE 067

the Ipi vs Nivo vs Ipi+Nivo study- the one that we don't like as underpowered to show a difference between Ipi+Nivo vs Nivo as THAT of course would have been the real question:

After 3 years, patients alive

34% with Ipi
52% with Nivo
58% with Ipi +Nivo

Compared to the 2 year OS of (was presented at AACR by J. Larkin in spring 2017):

45% with Ipi
59% with Nivo
64% with Ipi+ Nivo

So you indeed see the flattening of the curve- remember: infliction point is around 3 years (that's when the curve bends towards the tail, so patients who reach this will in all likelihood STAY alive)

Important to note: patients WITH BRAF, so BRAF pos did BETTER than BRAF wild-type patients, in particular on the Ipi plus Nivo combo (that's especially for the likes of HAS in France!!!) and this is the highest survival rate we've seen in advanced Melanoma. EVER.

3-year rates of overall survival of BRAF pos:

37% Ipi
56% Nivo

BUT this tops it all:
68% Ipi+ Nivo